DEINOVE AND GENOPLANTE VALOR AGREEMENT BOOST DEINOCHEM PROGRAMME DEVELOPMENTLicense Option Agreement • December 16th, 2013
Contract Type FiledDecember 16th, 2013Montpellier, December 17th 2013 - DEINOVE (Alternext Paris: ALDEI), a technological company that designs, develops and markets a new generation of industrial processes based on Deinococci bacteria, today announced the signing of a License Option Agreement with Génoplante Valor via INRA Transfert, a research enhancement subsidiary of the French National Institute in Agronomic Research that will cover the improvement of isoprenoid biosynthetic pathways. DEINOVE shall implement this technology in the DEINOCHEM programme to strengthen the Deinococcus bacterium’s capacity to produce chemicals from bio-based raw materials. This intellectual property has been generated as part of an ANR (National Research Agency) Genomics research programme labelled “Génoplante”. Patent details and conditions of acquisition of exploitation rights remain confidential.